Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S plus standard of care vs standard of care as maintenance in recurrent platinum-sensitive ovarian cancer
jRCT2051250197Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in high-grade serous carcinoma (HGSC), Endometrioid Cystadenocarcinoma, primary peritoneal cancer (PPC) and 2 more comparing Rina-S + SOC (bevacizumab or observation) with SOC (bevacizumab or observation) (2 arms). Primary endpoint: Progression-free survival (PFS) per RECIST 1.1 (investigator assessment). Started Apr 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
high-grade serous carcinoma (HGSC)Endometrioid Cystadenocarcinomaprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)ovarian cancer
Beyond the preview
Go deeper on jRCT2051250197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250197.